ArticleNeurology(R) neuroimmunology & neuroinflammation2021
Chitinase 3-like 1 and neurofilament light chain in CSF and CNS atrophy in MS.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis.Neurology(R) neuroimmunology & neuroinflammation · 2022Pooled it
- GFAP, CHI3L1 and GCIPL Thickness as Baseline Predictors of Early Disability Progression in MS.International journal of molecular sciences · 2025Observational
- Plasma CHI3L1 associates with brain volume loss and glial activation in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Peripheral cytokine and monocyte phenotype associations in drug-resistant epilepsy.Scientific reports · 2025Article
- Chitinase-3-Like 1 Protein (CHI3L1) Levels in Patients With Cognitive Deficits and Movement Disorders: Comparison With Other Biomarkers.Brain and behavior · 2025Article
- Chitinase-3-like-1: a multifaceted player in neuroinflammation and degenerative pathologies with therapeutic implications.Molecular neurodegeneration · 2025Review
- Review
- Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.International journal of molecular sciences · 2024Review
- Article
- Invasive growth of brain metastases is linked to CHI3L1 release from pSTAT3-positive astrocytes.Neuro-oncology · 2024Article
- Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- A rapid review of differences in cerebrospinal neurofilament light levels in clinical subtypes of progressive multiple sclerosis.Frontiers in neurology · 2024Review
- Chitinase-3-like 1-protein in CSF: a novel biomarker for progression in patients with multiple sclerosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Article
- The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?International journal of molecular sciences · 2023Review
- Protein biomarkers in multiple sclerosis.Encephalitis (Seoul, Korea) · 2023Review
- Chitinase Signature in the Plasticity of Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Demographic and disease-related factors impact on cerebrospinal fluid neurofilament light chain levels in multiple sclerosis.Brain and behavior · 2023Article
- Biomarkers in autoimmune diseases of the central nervous system.Frontiers in immunology · 2023Review
- Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- Toward Precision Phenotyping of Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate cross-sectional associations of CSF levels of neurofilament light chain (NfL) and of the newly emerging marker chitinase 3-like protein 1 (CHI3L1) with brain and spinal cord atrophy, which are established MRI markers of disease activity in MS, to study CHI3L1 and NfL in relapsing (RMS) and progressive MS (PMS), and to assess the expression of CHI3L1 in different cell types.
methodsIn a single-center study, 131 patients with MS (42 RMS and 89 PMS) were assessed for NfL and CHI3L1 concentrations in CSF, MRI-based spinal cord and brain volumetry, MS subtype, age, disease duration, and disability. We included 42 matched healthy controls receiving MRI. CHI3L1 expression of human brain cell types was examined in 2 published single-cell RNA sequencing data sets.
resultsCHI3L1 was associated with spinal cord volume (B = -1.07, 95% CI -2.04 to -0.11,
conclusionsNfL and CHI3L1 in CSF were differentially related to brain and spinal cord atrophy. CSF CHI3L1 was associated with spinal cord volume loss and was less affected than NfL by disease duration and age, whereas CSF NfL was associated with brain gray matter atrophy. CSF NfL and CHI3L1 measurement provides complementary information regarding brain and spinal cord volumes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CSF CHI3L1 is associated with spinal cord volume loss and that CSF NfL is associated with gray matter atrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.